<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pilot Feasibility Stud</journal-id><journal-id journal-id-type="iso-abbrev">Pilot Feasibility Stud</journal-id><journal-title-group><journal-title>Pilot and Feasibility Studies</journal-title></journal-title-group><issn pub-type="epub">2055-5784</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27965877</article-id><article-id pub-id-type="pmc">5153915</article-id><article-id pub-id-type="publisher-id">104</article-id><article-id pub-id-type="doi">10.1186/s40814-016-0104-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Survivors of intensive care with type 2 diabetes and the effect of shared care follow-up clinics: study protocol for the SWEET-AS randomised controlled feasibility study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3340-1965</contrib-id><name><surname>Ali Abdelhamid</surname><given-names>Yasmine</given-names></name><address><email>yasmine.aliabdelhamid@adelaide.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Phillips</surname><given-names>Liza</given-names></name><address><email>liza.phillips@adelaide.edu.au</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Horowitz</surname><given-names>Michael</given-names></name><address><email>michael.horowitz@adelaide.edu.au</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Deane</surname><given-names>Adam</given-names></name><address><email>adam.deane@adelaide.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Intensive Care Unit, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000 Australia </aff><aff id="Aff2"><label>2</label>Discipline of Acute Care Medicine, The University of Adelaide, North Terrace, Adelaide, South Australia 5000 Australia </aff><aff id="Aff3"><label>3</label>Endocrine and Metabolic Unit, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000 Australia </aff><aff id="Aff4"><label>4</label>Discipline of Medicine, The University of Adelaide, North Terrace, Adelaide, South Australia 5000 Australia </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>2</volume><elocation-id>62</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>1</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Many patients who survive the intensive care unit (ICU) experience long-term complications such as peripheral neuropathy and nephropathy which represent a major source of morbidity and affect quality of life adversely. Similar pathophysiological processes occur frequently in ambulant patients with diabetes mellitus who have never been critically ill. Some 25&#x000a0;% of all adult ICU patients have diabetes, and it is plausible that ICU survivors with co-existing diabetes are at heightened risk of sequelae from their critical illness.</p><p>ICU follow-up clinics are being progressively implemented based on the concept that interventions provided in these clinics will alleviate the burdens of survivorship. However, there is only limited information about their outcomes. The few existing studies have utilised the expertise of healthcare professionals primarily trained in intensive care and evaluated heterogenous cohorts. A shared care model with an intensivist- and diabetologist-led clinic for ICU survivors with type 2 diabetes represents a novel targeted approach that has not been evaluated previously. Prior to undertaking any definitive study, it is essential to establish the feasibility of this intervention.</p></sec><sec><title>Methods</title><p>This will be a prospective, randomised, parallel, open-label feasibility study. Eligible patients will be approached before ICU discharge and randomised to the intervention (attending a shared care follow-up clinic 1&#x000a0;month after hospital discharge) or standard care. At each clinic visit, patients will be assessed independently by both an intensivist and a diabetologist who will provide screening and targeted interventions. Six months after discharge, all patients will be assessed by blinded assessors for glycated haemoglobin, peripheral neuropathy, cardiovascular autonomic neuropathy, nephropathy, quality of life, frailty, employment and healthcare utilisation. The primary outcome of this study will be the recruitment and retention at 6&#x000a0;months of all eligible patients.</p></sec><sec><title>Discussion</title><p>This study will provide preliminary data about the potential effects of critical illness on chronic glucose metabolism, the prevalence of microvascular complications, and the impact on healthcare utilisation and quality of life in intensive care survivors with type 2 diabetes. If feasibility is established and point estimates are indicative of benefit, funding will be sought for a larger, multi-centre study.</p></sec><sec><title>Trial registration</title><p>ANZCTR <ext-link ext-link-type="uri" xlink:href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369741">ACTRN12616000206426</ext-link>
</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Intensive care</kwd><kwd>Critical illness</kwd><kwd>Survivors</kwd><kwd>Diabetes mellitus</kwd><kwd>Follow-up studies</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009327</institution-id><institution>Intensive Care Foundation</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004267</institution-id><institution>Royal Adelaide Hospital</institution></institution-wrap></funding-source><award-id>AR Clarkson Scholarship</award-id><award-id>Research Committee Early Career Fellowship</award-id><principal-award-recipient><name><surname>Ali Abdelhamid</surname><given-names>Yasmine</given-names></name><name><surname>Phillips</surname><given-names>Liza</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>Early Career Fellowship</award-id><principal-award-recipient><name><surname>Deane</surname><given-names>Adam</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Acute hospital mortality for patients admitted to intensive care units (ICUs) has decreased substantially in the past two decades [<xref ref-type="bibr" rid="CR1">1</xref>]. However, longer-term outcomes for those who survive hospital discharge remain poor, with approximately 40&#x000a0;% of patients dying in the 5&#x000a0;years after hospital discharge [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. This &#x02018;legacy effect&#x02019; of critical illness on the risk of death is consistent across studies from various regions and appears to persist for at least 15&#x000a0;years after the index admission [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>In addition to being a strong predictor of death, an episode of critical illness leads to substantial morbidity, with survivors frequently experiencing long-term physical and neuropsychiatric problems including weakness, impaired physical function, depression, anxiety, and cognitive dysfunction [<xref ref-type="bibr" rid="CR5">5</xref>]. Moreover, the morbidity of chronic illness is exacerbated by ICU admission. For example, in an important longitudinal study of 109 ICU survivors followed for 5&#x000a0;years, for each additional chronic illness, healthcare expenditure increased threefold after hospital discharge [<xref ref-type="bibr" rid="CR6">6</xref>]. Because the long-term effect of a single episode of critical illness on health is substantial, and the costs associated with care of survivors, particularly those with pre-existing chronic illnesses, are considerable, there is an urgent need for interventions that modify these outcomes in patients with chronic illnesses.</p><p>Diabetes, particularly type 2 diabetes, is a frequently co-existing illness in critically ill patients, with a reported prevalence ranging from 12 to 30&#x000a0;% in observational studies [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. However, it is likely that the true prevalence has been under-represented in these studies due to diabetes that is either not documented or recognised [<xref ref-type="bibr" rid="CR12">12</xref>]. While diabetes per se has been identified as a risk factor for the development of critical illness, as well as the severity of the illness [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], and the presence of diabetes is associated with a greater number of other co-existing chronic illnesses, it is surprising that there does not appear to be any association between the presence of diabetes and the risk of death within the index hospital admission. Indeed, several studies have now reported that patients with diabetes have comparable, or slightly lower, ICU and hospital mortality rates when compared to patients without diabetes [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. While it is plausible that ICU survivors with diabetes are more likely to experience greater long-term morbidity and mortality than survivors without diabetes, this has not been evaluated and the long-term effects of critical illness on patients with diabetes are unknown.</p><p>It is notable that many of the complications which occur in the critically ill are also well-recognised microvascular complications which are prevalent in ambulant patients with diabetes. Autonomic neuropathy, sensorimotor peripheral neuropathy and nephropathy are all common in survivors of critical illness [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>] as well as in patients with type 2 diabetes who have never been critically ill [<xref ref-type="bibr" rid="CR20">20</xref>]. It would, therefore, not be surprising if these disease processes are additive, or even synergistic, so that an episode of critical illness has the potential to exacerbate any underlying complications of diabetes, but this has not previously been investigated.</p><p>Critical illness polyneuropathy affects up to half of ICU survivors [<xref ref-type="bibr" rid="CR18">18</xref>]. Critical illness polyneuropathy is an axonal degenerative condition and, although multiple mechanisms are implicated, hyperglycaemia is strongly associated with its development [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], as is well established to be the case for the microvascular complications of diabetes [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Patients with critical illness polyneuropathy experience weakness, which can be profound and associated with considerable disability. Recovery is typically slow and may occur over years; indeed in some cases, the polyneuropathy never resolves completely [<xref ref-type="bibr" rid="CR25">25</xref>]. Similarly, acute cardiovascular autonomic neuropathy also occurs frequently during critical illness, even in those not known to have diabetes, and is strongly associated with day-28 mortality [<xref ref-type="bibr" rid="CR17">17</xref>]. In ambulant patients with type 2 diabetes, cardiovascular autonomic neuropathy is now recognised as an important predictor of cardiovascular death and has a greater impact than &#x02018;traditional&#x02019; cardiovascular risk factors such as hypertension and hyperlipidaemia [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. During critical illness, patients also often have markedly delayed gastric emptying [<xref ref-type="bibr" rid="CR29">29</xref>], and survivors frequently report sexual and bladder dysfunction [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], all of which may be manifestations of underlying autonomic neuropathy similar to that which occurs in patients with diabetes [<xref ref-type="bibr" rid="CR32">32</xref>]. However, whether autonomic neuropathy occurs frequently in ICU survivors with pre-existing type 2 diabetes, as well as the natural history and clinical implications of this condition, are unknown.</p><p>In critically ill patients who develop acute kidney injury requiring renal replacement therapy, short-term mortality is very high [<xref ref-type="bibr" rid="CR19">19</xref>], even in those who survive hospitalisation [<xref ref-type="bibr" rid="CR33">33</xref>]. Moreover, survivors also report reductions in physical function and mental health 3&#x000a0;years after ICU discharge [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], long-term mortality rates are considerable (&#x0003e;60&#x000a0;%) and chronic albuminuria is present in almost half of those alive at 4&#x000a0;years [<xref ref-type="bibr" rid="CR33">33</xref>]. The latter is known to be an independent risk factor for cardiovascular disease, requirement for dialysis, and death in cohorts of patients with chronic kidney disease, as well as in epidemiological studies of the general population [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. It is conceivable, therefore, that longitudinal outcomes will be worse in critically ill patients with diabetes, particularly given that albuminuria is a key feature of diabetic nephropathy.</p><p>Microvascular complications, including cardiovascular autonomic neuropathy, account for much of the morbidity and healthcare costs associated with type 2 diabetes. However, there is compelling evidence that comprehensive interventions can reduce the incidence and progression of these complications [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Longer-term cardiovascular risk may also be reduced with attention to glucose control [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]; however, tailoring of glycaemic targets to individual circumstances is an important consideration, particularly in the older population [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. These observations suggest that early, and ongoing, intervention from a physician with expertise in the management of type 2 diabetes and its complications will be important in this patient cohort.</p><p>In contrast, the evidence base for interventions following ICU discharge is more limited. Because survivors of critical illness experience profound physical symptoms for prolonged periods of time after discharge, programmes of follow-up care have been proposed to alleviate the burdens of survivorship [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. There are, however, no data to support the use of ICU follow-up clinics [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Not only are there few randomised controlled studies, but the existing studies have employed a variety of interventions and outcome measures, compromising direct comparison [<xref ref-type="bibr" rid="CR44">44</xref>]. The largest study to date enrolled 286 ICU survivors and randomised them to a nurse-led intensive care follow-up clinic or standard care [<xref ref-type="bibr" rid="CR45">45</xref>]. Twelve months after ICU discharge, there was no evidence of benefit for patients randomised to the follow-up programme and the programme was, accordingly, not cost effective. A more recent multi-centre study evaluated a hospital-based rehabilitation programme of increased physical and nutritional therapies, combined with provision of illness-specific information, after ICU discharge [<xref ref-type="bibr" rid="CR46">46</xref>]. The intervention had no effect on mobility, self-reported symptoms or health-related quality of life (HRQoL) at either 3&#x000a0;months, or at the 12-month follow-up. The lack of effect observed in these studies may represent a true result or a type II error. Importantly, it should be recognised that these programmes, as is the case with the majority of studies in this field of research, were conducted in heterogeneous patient cohorts and the inclusion of patients with numerous and multiple chronic diseases, many of which may be outside the sphere of expertise of healthcare professionals practising in intensive care, may have contributed to the apparent lack of benefit. Furthermore, the largest study [<xref ref-type="bibr" rid="CR45">45</xref>] included patients with only an overnight stay in ICU and it is plausible that patients with greater illness severity and longer ICU stays are most likely to benefit from a follow-up intervention. Accordingly, in the proposed study, the health service intervention will be applied to a defined group of survivors (patients with type 2 diabetes who have had a significant ICU stay) and will utilise physicians with distinct, but complementary, expertise.</p><p>Despite the limited evidence, ICU follow-up clinics have proliferated in many countries, and generally in an ad hoc fashion, rather than in a systematic framework with rigorous evaluation of benefit [<xref ref-type="bibr" rid="CR44">44</xref>]. However, international guidelines recommend that all ICU survivors are reviewed 2 to 3&#x000a0;months following hospital discharge at a follow-up clinic [<xref ref-type="bibr" rid="CR47">47</xref>]. Given the considerable expenditure of such a health service programme, it is essential that its potential effectiveness is established and quantified, prior to implementation.</p><sec id="Sec2"><title>Study objectives</title><p>The objective of this study is to establish the feasibility of conducting a definitive trial to evaluate the benefits of a shared care intensivist and diabetologist-led clinic for ICU survivors with pre-existing type 2 diabetes. Feasibility will be established by quantifying:<list list-type="simple"><list-item><label>(i)</label><p>Study processes&#x02014;the rate of recruitment of study participants using the proposed inclusion and exclusion criteria over 12&#x02013;18&#x000a0;months and the rate of retention of the participants for a 6-month period</p></list-item><list-item><label>(ii)</label><p>Resources required&#x02014;an accurate estimate of time and budget requirements</p></list-item><list-item><label>(iii)</label><p>Scientific effects&#x02014;preliminary data relating to the potential effects of critical illness on chronic glucose metabolism, the prevalence of complications and the impact on healthcare utilisation and quality of life in intensive care survivors with type 2 diabetes. These data are necessary for confirmation of our initial calculation of sample size for the major study.</p></list-item></list>
</p></sec></sec><sec id="Sec3"><title>Methods/design</title><p>This will be a prospective, randomised, parallel, open-label, single-centre, feasibility study with allocation concealment and blinded assessors. The study has been designed in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT 2013) [<xref ref-type="bibr" rid="CR48">48</xref>] and the Consolidated Standards for Reporting of Trials CONSORT guidelines [<xref ref-type="bibr" rid="CR49">49</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, study flow diagram). The study will be undertaken at the university-affiliated tertiary care hospital - the Royal Adelaide Hospital, Adelaide, Australia.<fig id="Fig1"><label>Fig. 1</label><caption><p>Study flow diagram. Flow diagram of patient recruitment and study conduct</p></caption><graphic xlink:href="40814_2016_104_Fig1_HTML" id="MO1"/></fig>
</p><sec id="Sec4"><title>Study participants</title><p>Participants will be recruited from those patients being discharged from the ICU at the Royal Adelaide Hospital over a 12 to 18-month period (between February 2016 and August 2017). Patients will be approached once they become eligible and liberated from mechanical ventilation. Inclusion and exclusion criteria are described in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Type 2 diabetes will be defined according to national guidelines [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Patient consent will be obtained by one of the investigators.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="2">Inclusion criteria</td></tr><tr><td colspan="2">&#x02003;Established pre-admission diagnosis of type 2 diabetes mellitus</td></tr><tr><td colspan="2">&#x02003;Discharged from ICU after &#x02265;5&#x000a0;days of ICU care</td></tr><tr><td colspan="2">Exclusion criteria</td></tr><tr><td colspan="2">&#x02003;Distance from hospital to home &#x0003e;50&#x000a0;km</td></tr><tr><td colspan="2">&#x02003;Age &#x0003e;85&#x000a0;years</td></tr><tr><td colspan="2">&#x02003;Major psychiatric illness</td></tr><tr><td colspan="2">&#x02003;Anticipated to die within 6&#x000a0;months of ICU discharge</td></tr><tr><td colspan="2">&#x02003;Pregnancy</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec5"><title>Baseline data collection</title><p>Baseline data, including patient demographics, admission diagnosis, ICU length of stay, severity of illness according to acute physiology, age and chronic health evaluation (APACHE) II and sequential organ failure assessment (SOFA) scoring systems [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>], kidney injury during ICU admission utilising the RIFLE criteria [<xref ref-type="bibr" rid="CR54">54</xref>] and serum urea and creatinine levels, employment status, degree of frailty before hospital admission as measured by the Canadian Study on Health and Aging Clinical Frailty Scale [<xref ref-type="bibr" rid="CR55">55</xref>], diabetes duration and treatment, and glycated haemoglobin level will be recorded. Information regarding consent processes will be collected.</p></sec><sec id="Sec6"><title>Randomisation</title><p>All patients who provide consent for participation and fulfil the inclusion criteria will undergo simple randomisation to either the intervention or control group with a 1:1 allocation by a computerised random number generator; <ext-link ext-link-type="uri" xlink:href="https://www.randomizer.org/">https://www.randomizer.org</ext-link>. The randomisation sequence will be generated, and study arm allocation will be assigned by a designated research coordinator who is not involved in the study. The randomisation sequence will be concealed from the staff enrolling and consenting participants to prevent selection bias. The randomisation sequence will be protected by an electronic password known only to the designated research coordinator.</p></sec><sec id="Sec7"><title>Intervention group</title><p>Patients in the intervention group will be asked to record their blood glucose level after discharge using a provided form. Patients receiving oral hypoglycaemic agents alone will be asked to record their daily fasting blood glucose level, followed by levels twice daily in the week prior to attendance at the follow-up clinic. Patients receiving subcutaneous insulin will be asked to record their blood glucose level at least twice daily after discharge until review at the clinic. When feasible, patients will undergo continuous glucose monitoring in the week prior to clinic attendance.</p><p>All patients in the intervention group will receive a telephone call 2&#x000a0;weeks after hospital discharge as a reminder of the upcoming clinic appointment. During this phone call, inquiries about hypoglycaemic (blood glucose level &#x0003c;4&#x000a0;mmol/L) or hyperglycaemic (blood glucose level &#x0003e;13&#x000a0;mmol/L) blood concentrations will be made. If necessary, changes in treatment will be instituted by the study diabetologist and recorded for each patient. Patients will also undergo blood testing for glycated haemoglobin, complete blood count, electrolytes, renal and liver function, calcium profile, vitamin D level, lipid profile, vitamin B<sub>12</sub> level, folate level, iron studies, thyroid function, gonadotropin levels and testosterone level (male patients) during the week prior to the clinic attendance and prior to the 6-month assessment. Fructosamine will be measured as an additional marker of glycaemic control prior to the clinic attendance [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p>Attendance at the shared care follow-up clinic will occur 1&#x000a0;month after hospital discharge (&#x000b1;14&#x000a0;days). Patients will be assessed by both an intensivist and a diabetologist at the clinic as outlined in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Evaluation at the ICU follow-up clinic</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Diabetologist assessment</th><th>Intensivist assessment</th></tr></thead><tbody><tr><td>Anthropometric measurements</td><td>Semi-structured interview to assess for long-term complications of ICU admission</td></tr><tr><td>History of diabetes and treatment</td><td>Discussion of ICU experience</td></tr><tr><td>Review of blood glucose levels and diabetes medications</td><td>Assessment of mobility</td></tr><tr><td>Assessment of cardiovascular risk</td><td>Screen for anxiety and depression</td></tr><tr><td>&#x02003;&#x02022; Blood pressure check and titration of antihypertensives</td><td>Assessment of employment status and frailty</td></tr><tr><td>&#x02003;&#x02022; Lipids</td><td>Quality of life questionnaire</td></tr><tr><td>&#x02003;&#x02022; Indication for aspirin</td><td>Review of patient healthcare utilisation diary</td></tr><tr><td>Diabetes complications screen</td><td>Referral to other specialists or services as required</td></tr><tr><td>&#x02003;&#x02022; Nephropathy</td><td/></tr><tr><td>&#x02003;&#x02022; Peripheral neuropathy</td><td rowspan="2"/></tr><tr><td>&#x02003;&#x02022; Cardiovascular autonomic neuropathy</td></tr><tr><td>&#x02003;&#x02022; Retinopathy</td><td rowspan="3"/></tr><tr><td>&#x02003;&#x02022; Macrovascular complications</td></tr><tr><td>&#x02003;&#x02022; Referral to ophthalmologist or podiatrist as appropriate</td></tr></tbody></table></table-wrap>
</p><p>Evaluation will include measurement of vital signs and basic anthropometric data; history-taking regarding diabetes and its treatment; review of blood glucose levels and continuous glucose monitoring data; adjustment of oral hypoglycaemic agents or insulin dosing as required; overall medication review; and cardiovascular risk assessment. Glycaemic targets will be tailored for each patient taking into consideration diabetes duration, diabetes medication regimen, the presence of cardiovascular disease, comorbidities and problems with hypoglycaemia [<xref ref-type="bibr" rid="CR57">57</xref>]. Blood pressure, lipid profile and requirement for aspirin will be assessed and treatment instituted based upon published guidelines for patients with diabetes [<xref ref-type="bibr" rid="CR58">58</xref>]. Patients will also undergo evaluation for complications of diabetes including nephropathy (serum urea and creatinine, spot and, if required 24-h, urine albumin) [<xref ref-type="bibr" rid="CR59">59</xref>]; distal peripheral sensorimotor neuropathy [<xref ref-type="bibr" rid="CR60">60</xref>]; cardiovascular autonomic neuropathy using validated cardiovascular autonomic reflex tests [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>] performed by ANX 3.0 Autonomic Nervous System monitoring technology (The ANSAR Group, Philadelphia, USA) and macrovascular complications (ischaemic stroke, myocardial ischaemia, peripheral vascular disease) when appropriate.</p><p>Patients and, if necessary, their carers will be interviewed and systematically asked about any problems which have developed since ICU admission including pain, airway obstruction, symptoms of autonomic neuropathy, sexual dysfunction, concerns about cosmesis and any impairments of vision, hearing, taste, swallowing, appetite, cognition or communication as recommended in international clinical guidelines [<xref ref-type="bibr" rid="CR47">47</xref>]. Such systematic interviewing has been used previously in the ICU follow-up clinic setting [<xref ref-type="bibr" rid="CR6">6</xref>]. Patients will be screened for mobility limitations using the Modified Rivermead Mobility Index [<xref ref-type="bibr" rid="CR63">63</xref>], and patients of concern will be referred to the physiotherapy department of the hospital. The ICU experience will be discussed, and patients will be screened for psychological distress using the Hospital Anxiety and Depression Scale (HADS) [<xref ref-type="bibr" rid="CR64">64</xref>]. Patients with a high HADS score will be referred to the hospital&#x02019;s psychology clinic if eligible, or otherwise to their general practitioner for formation of a Medicare-funded Mental Health Treatment Plan. Both the Modified Rivermead Mobility Index and the HADS have been previously used in studies of ICU survivors [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p><p>Following the above assessments and discussion between the intensivist and diabetologist, patients may require referral to additional healthcare professionals, including diabetes nurse educators, podiatrists, ophthalmologists, dietitians and other medical or surgical specialists. All referrals will follow standard hospital pathways. If deemed required, an additional clinic visit will be offered to patients in the intervention group prior to the assessment at 6&#x000a0;months. A written summary of the outcomes from the clinic visit/s will be provided to each patient&#x02019;s general practitioner.</p></sec><sec id="Sec8"><title>Control group</title><p>Patients in the control group will have usual care in accordance with standard clinical practice, so that follow-up after ICU will be at the discretion of the primary inpatient hospital team and the patient&#x02019;s general practitioner.</p><p>Patients will undergo blood testing for glycated haemoglobin, complete blood count, electrolytes, renal and liver function, calcium profile, vitamin D level, lipid profile, vitamin B<sub>12</sub> level, folate level, iron studies, thyroid function, gonadotropin levels and testosterone level (male patients) during the week prior to the 6-month assessment.</p></sec><sec id="Sec9"><title>Outcome measures</title><p>All patients in the intervention and control groups will be contacted by mail and telephone and invited back at 6&#x000a0;months after hospital discharge for assessment. Patients will be assessed by two blinded assessors (an intensivist and a diabetologist) who were not present at the follow-up clinic. Before undergoing this assessment, patients in the intervention group will be instructed not to refer to their prior attendance at the follow-up clinic so that the assessors remain blinded.</p><sec id="Sec10"><title>Primary outcome</title><p>The primary outcomes of this study are the recruitment rate over the 12 to 18-month recruitment period of the study and the rate of retention of enrolled patients for six months. The number of eligible patients during the recruitment period will be recorded, along with reasons for refusal of consent. Success of the feasibility study will be determined if &#x02265;50&#x000a0;% of all eligible patients are recruited and complete six-month data is obtained in &#x02265;80&#x000a0;% of these patients.</p></sec><sec id="Sec11"><title>Secondary outcomes</title><p>A number of secondary outcomes will be collected for descriptive purposes. Anthropometric data based on Australian longitudinal studies of ambulant patients with type 2 diabetes will be collected [<xref ref-type="bibr" rid="CR65">65</xref>]. Glycated haemoglobin will be quantified as a marker of glycaemic control using high-performance liquid chromatography [<xref ref-type="bibr" rid="CR56">56</xref>]. The capacity of patients using insulin or sulphonylureas to detect hypoglycaemia and symptoms of hypoglycaemia will be assessed using a validated questionnaire (the Clarke score) [<xref ref-type="bibr" rid="CR66">66</xref>]. Patients will be assessed for the presence of distal symmetrical peripheral neuropathy with the Michigan Neuropathy Screening Instrument, a simple non-invasive and valid measure comparable to the &#x02018;gold standard&#x02019; of an examination performed by a neurologist combined with electrophysiology examinations [<xref ref-type="bibr" rid="CR60">60</xref>]. Testing for cardiovascular autonomic neuropathy will be performed using the ANX 3.0 Autonomic Nervous System monitoring technology (The ANSAR Group, Philadelphia, USA) according to the latest consensus guidelines for the diagnosis of autonomic dysfunction and patients categorised as having autonomic dysfunction if two or more tests are outside the age-adjusted reference range [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. The sympathetic response will be evaluated following the Valsalva manoeuvre for those unable to perform orthostatic provocation [<xref ref-type="bibr" rid="CR61">61</xref>]. Patients will be screened for nephropathy with serum urea and creatinine and spot urine testing. If two spot urine samples are suggestive of macroalbuminuria, urine will be collected for 24&#x000a0;h and analysed for protein [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p>HRQoL scores will be measured with the EuroQol EQ-5D-5L and the short form-36 (SF-36) survey [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Both instruments are valid and sensitive, have been used in studies of ICU survivors, and demonstrate good completion rates by telephone or mail if necessary [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Rates of HRQoL questionnaire completion will be reported. HRQoL scores have been used as the primary outcome in the largest study of ICU follow-up clinics to date [<xref ref-type="bibr" rid="CR45">45</xref>] and, if high HRQoL questionnaire completion rates are demonstrated in this feasibility study, the general health component of the SF-36 will serve as the primary outcome of a subsequent larger study.</p><p>Additional secondary outcomes related to functioning in the community and healthcare resource use will also be collected. These outcomes may also serve as secondary outcomes in a subsequent larger study. The degree of frailty will be assessed using the Canadian Study on Health and Aging Clinical Frailty Scale [<xref ref-type="bibr" rid="CR55">55</xref>], a validated tool which has previously been used in the Australian ICU setting [<xref ref-type="bibr" rid="CR71">71</xref>] and may predict outcomes in critically ill patients [<xref ref-type="bibr" rid="CR72">72</xref>]. Employment status will be recorded. Healthcare utilisation data will be collected prospectively using patient monthly diaries and corroborated with hospital inpatient and outpatient clinical records and self-reports at scheduled study visits. This validated approach provides patient-specific and activity-based resource-use data after hospital discharge [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. We will specifically collect data about hospital and ICU readmissions; inpatient and outpatient rehabilitation service utilisation; hospital emergency room and outpatient clinic visits; general practitioner and specialist visits; diagnostic tests; home care services and provision of specialised medical equipment. If required when an inpatient admission occurs, we will obtain (with the patient&#x02019;s consent) the medical record to confirm the dates of admission, reason for admission and types of treatment received.</p><p>The outcome measures will be taken 6&#x000a0;months after hospital discharge by blinded assessors. EuroQol EQ-5D-5L scores, employment status and healthcare utilisation data will also be collected during the follow-up clinic visit 1&#x000a0;month after hospital discharge in the intervention group. Patients failing to attend the assessment visit will be contacted by telephone and/or mail, provided with the relevant questionnaires for completion, and asked to make their diaries available to the research team. Reasons for non-attendance at the clinic and the assessment appointment will be recorded.</p><p>The resources necessary for the study will also be quantified. This will include the hours per week a research coordinator is employed to assist with screening, recruitment and data management. The cost of employing the research coordinator will be calculated. The time required for the diabetologist and intensivist to assess each patient at the follow-up clinic, as well during the 6-month outcome assessment visit, will be recorded. The cost of all blood tests requested will be quantified. The amount of any honoraria paid to participants to cover transport costs and the participants&#x02019; time will also be collected.</p></sec></sec><sec id="Sec12"><title>Analysis plan</title><p>For the main SWEET-AS study, the target sample will be 206 study participants. This is based on previous local mean values for the physical component summary score of the SF-36 of 41 with standard deviation of 10 [<xref ref-type="bibr" rid="CR74">74</xref>], setting a clinically meaningful difference of 5, and allowing for 20&#x000a0;% drop outs, which will provide 90&#x000a0;% power (alpha 0.05) using two-tailed testing.</p><p>Based upon data from the Royal Adelaide Hospital [<xref ref-type="bibr" rid="CR7">7</xref>], it is anticipated that there will be 80 eligible patients over the 12-month feasibility study period. The study will, accordingly, be deemed successful if at least 40 patients are recruited (50&#x000a0;% of all eligible patients) and complete 6-month data is obtained for at least 32 patients (80&#x000a0;% retention rate). If participant recruitment is significantly less than this, the study can be extended for a further 6&#x02013;12&#x000a0;months.</p><p>Baseline comparison of patient demographics, severity of illness scores and ICU length of stay will be presented. Other scientific outcomes measured at 6&#x000a0;months after ICU discharge (glycated haemoglobin, HRQoL scores, Michigan neuropathy score, Clarke hypoglycaemia score, presence of cardiovascular autonomic neuropathy and nephropathy) will be reported for the entire cohort as a whole, allowing the participant data to be included in the main larger study. Reasons for missing data will be reported. Healthcare utilisation data will be reported descriptively, including the number of hospital and ICU readmissions, emergency room visits, general practitioner and specialist visits, and attendances at inpatient or outpatient rehabilitation services.</p></sec></sec><sec id="Sec13"><title>Discussion</title><p>With regard to both methodological and mechanistic perspectives, this study has a number of strengths. Methodological strengths include the use of consecutive enrolment, patient randomisation and blinded outcome assessment. The major mechanistic strength is that this is the first study to enrol a subgroup of ICU survivors with a defined chronic illness and incorporate focused multidisciplinary care. Furthermore, this subgroup of patients with type 2 diabetes and a significant ICU length of stay is an at-risk group likely to benefit from such a follow-up intervention. The patients will also attend the follow-up clinic earlier than was the case in the previous largest trial of ICU follow-up [<xref ref-type="bibr" rid="CR45">45</xref>] which may prove beneficial.</p><p>Dependent on the outcome of this feasibility study, the follow-up clinic will either be continued with the view to expansion and undertaking a definitive study, or the patients will return to the care of their general practitioners and/or diabetologists.</p></sec><sec id="Sec14"><title>Conclusions</title><p>Intensive care treatment saves lives, but the burden of survivorship is substantial and survivors with type 2 diabetes may well face greater challenges than those without co-existing chronic illness. ICU follow-up clinics are increasingly being introduced in an effort to improve outcomes, but the evidence to support their use is limited. The proposed intervention represents a novel approach to ICU follow-up clinics, and this study will determine the feasibility of such an approach, with an ultimate goal of identifying an evidence-based targeted intervention to improve outcomes in patients with type 2 diabetes following ICU discharge.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>APACHE</term><def><p>Acute physiology, age and chronic health evaluation</p></def></def-item><def-item><term>CONSORT</term><def><p>Consolidated Standards for Reporting of Trials</p></def></def-item><def-item><term>HADS</term><def><p>Hospital Anxiety and Depression Scale</p></def></def-item><def-item><term>HRQoL</term><def><p>Health-related quality of life</p></def></def-item><def-item><term>ICU</term><def><p>Intensive care unit</p></def></def-item><def-item><term>RIFLE</term><def><p>Risk, injury, failure, loss, end-stage kidney disease</p></def></def-item><def-item><term>SF-36</term><def><p>Short-form 36 health survey</p></def></def-item><def-item><term>SOFA</term><def><p>Sequential organ failure assessment</p></def></def-item><def-item><term>SPIRIT</term><def><p>Standard protocol items: recommendations for interventional trials</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Ms. Kylie Lange (Biostatistician, Centre of Research Excellence in Translating Nutritional Science to Good Health, Discipline of Medicine, University of Adelaide) reviewed the manuscript and provided statistical advice.</p><sec id="FPar1"><title>Funding</title><p>This study is funded by an Intensive Care Foundation research grant. Dr. Ali Abdelhamid is a recipient of a Royal Adelaide Hospital Research Committee AR Clarkson Scholarship. Dr. Phillips is supported by a Royal Adelaide Hospital Research Committee Early Career Fellowship. Dr. Deane is supported by a National Health and Medical Research Council Early Career Fellowship.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>Not applicable.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>All authors contributed to the study design and critically reviewed the manuscript for important scientific content. YA and AD drafted the manuscript. All authors reviewed the final manuscript and agree to be accountable for the accuracy and integrity of the work.</p></sec><sec id="FPar4"><title>Authors&#x02019; information</title><p>Nil additional.</p></sec><sec id="FPar5"><title>Competing interests</title><p>The authors declare that there are no non-financial competing interests. Dr. Phillips has received honoraria or research support from GlaxoSmithKline, Merck Sharp and Dohme, Novartis and Novo Nordisk. Prof Horowitz has participated in advisory boards and/or symposia for Novo/Nordisk, Sanofi-aventis, Novartis, Eli-Lily, Boehringer Ingelheim, AstraZeneca, Satlogen and Meyer Nutraceuticals. Dr. Deane has participated in advisory boards for Medtronic and Lyric Pharmaceutical.</p></sec><sec id="FPar6"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar7"><title>Ethics approval and consent to participate</title><p>This study will be conducted according to the principles established in the National Health and Medical Research Council National Statement on Ethical Conduct in Human Research and has been approved by the Royal Adelaide Hospital Research Ethics Committee (HREC/15/RAH/347). Informed consent will be sought from all participants. The trial has been registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12616000206426). Any adverse events associated with the trial will be reported to the Royal Adelaide Hospital Research Ethics Committee. All data obtained during the study will be coded, de-identified and stored in the secure area of the Royal Adelaide Hospital ICU Research Department. Only the investigators and staff of the Department will have access to the records.</p></sec><sec id="FPar8"><title>Dissemination</title><p>The results of this study will be submitted for publication to peer-reviewed journals and presented at national/international ICU conferences.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>JE</given-names></name><name><surname>Kramer</surname><given-names>AA</given-names></name><name><surname>Knaus</surname><given-names>WA</given-names></name></person-group><article-title>Changes in hospital mortality for United States intensive care unit admissions from 1988 to 2012</article-title><source>Crit Care</source><year>2013</year><volume>17</volume><fpage>R81</fpage><pub-id pub-id-type="doi">10.1186/cc12695</pub-id><pub-id pub-id-type="pmid">23622086</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>TA</given-names></name><name><surname>Dobb</surname><given-names>GJ</given-names></name><name><surname>Finn</surname><given-names>JC</given-names></name><name><surname>Knuiman</surname><given-names>MW</given-names></name><name><surname>Geelhoed</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><etal/></person-group><article-title>Determinants of long-term survival after intensive care</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><issue>5</issue><fpage>1523</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318170a405</pub-id><pub-id pub-id-type="pmid">18434893</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuthbertson</surname><given-names>BH</given-names></name><name><surname>Roughton</surname><given-names>S</given-names></name><name><surname>Jenkinson</surname><given-names>D</given-names></name><name><surname>Maclennan</surname><given-names>G</given-names></name><name><surname>Vale</surname><given-names>L</given-names></name></person-group><article-title>Quality of life in the five years after intensive care: a cohort study</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><issue>1</issue><fpage>R6</fpage><pub-id pub-id-type="doi">10.1186/cc8848</pub-id><pub-id pub-id-type="pmid">20089197</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niskanen</surname><given-names>M</given-names></name><name><surname>Kari</surname><given-names>A</given-names></name><name><surname>Halonen</surname><given-names>P</given-names></name></person-group><article-title>Five-year survival after intensive care&#x02014;comparison of 12,180 patients with the general population. Finnish ICU Study Group</article-title><source>Crit Care Med</source><year>1996</year><volume>24</volume><issue>12</issue><fpage>1962</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/00003246-199612000-00006</pub-id><pub-id pub-id-type="pmid">8968262</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>SV</given-names></name><name><surname>Law</surname><given-names>TJ</given-names></name><name><surname>Needham</surname><given-names>DM</given-names></name></person-group><article-title>Long-term complications of critical care</article-title><source>Crit Care Med</source><year>2011</year><volume>39</volume><issue>2</issue><fpage>371</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181fd66e5</pub-id><pub-id pub-id-type="pmid">20959786</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herridge</surname><given-names>MS</given-names></name><name><surname>Tansey</surname><given-names>CM</given-names></name><name><surname>Matte</surname><given-names>A</given-names></name><name><surname>Tomlinson</surname><given-names>G</given-names></name><name><surname>Diaz-Granados</surname><given-names>N</given-names></name><name><surname>Cooper</surname><given-names>A</given-names></name><etal/></person-group><article-title>Functional disability 5&#x000a0;years after acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>14</issue><fpage>1293</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1011802</pub-id><pub-id pub-id-type="pmid">21470008</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plummer</surname><given-names>MP</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Cousins</surname><given-names>CE</given-names></name><name><surname>Annink</surname><given-names>CE</given-names></name><name><surname>Sundararajan</surname><given-names>K</given-names></name><name><surname>Reddi</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality</article-title><source>Intensive Care Med</source><year>2014</year><volume>40</volume><issue>7</issue><fpage>973</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/s00134-014-3287-7</pub-id><pub-id pub-id-type="pmid">24760120</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermanides</surname><given-names>J</given-names></name><name><surname>Bosman</surname><given-names>RJ</given-names></name><name><surname>Vriesendorp</surname><given-names>TM</given-names></name><name><surname>Dotsch</surname><given-names>R</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>Zandstra</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Hypoglycemia is associated with intensive care unit mortality</article-title><source>Crit Care Med</source><year>2010</year><volume>38</volume><issue>6</issue><fpage>1430</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181de562c</pub-id><pub-id pub-id-type="pmid">20386307</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falciglia</surname><given-names>M</given-names></name><name><surname>Freyberg</surname><given-names>RW</given-names></name><name><surname>Almenoff</surname><given-names>PL</given-names></name><name><surname>D'Alessio</surname><given-names>DA</given-names></name><name><surname>Render</surname><given-names>ML</given-names></name></person-group><article-title>Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><issue>12</issue><fpage>3001</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181b083f7</pub-id><pub-id pub-id-type="pmid">19661802</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krinsley</surname><given-names>JS</given-names></name><name><surname>Egi</surname><given-names>M</given-names></name><name><surname>Kiss</surname><given-names>A</given-names></name><name><surname>Devendra</surname><given-names>AN</given-names></name><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Maurer</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study</article-title><source>Crit Care</source><year>2013</year><volume>17</volume><issue>2</issue><fpage>R37</fpage><pub-id pub-id-type="doi">10.1186/cc12547</pub-id><pub-id pub-id-type="pmid">23452622</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krinsley</surname><given-names>JS</given-names></name><name><surname>Schultz</surname><given-names>MJ</given-names></name><name><surname>Spronk</surname><given-names>PE</given-names></name><name><surname>Harmsen</surname><given-names>RE</given-names></name><name><surname>van Braam Houckgeest</surname><given-names>F</given-names></name><name><surname>van der Sluijs</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Mild hypoglycemia is independently associated with increased mortality in the critically ill</article-title><source>Crit Care</source><year>2011</year><volume>15</volume><issue>4</issue><fpage>R173</fpage><pub-id pub-id-type="doi">10.1186/cc10322</pub-id><pub-id pub-id-type="pmid">21787410</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kar</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>KL</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Deane</surname><given-names>AM</given-names></name></person-group><article-title>Management of critically ill patients with type 2 diabetes: the need for personalised therapy</article-title><source>World J Diabetes</source><year>2015</year><volume>6</volume><issue>5</issue><fpage>693</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.4239/wjd.v6.i5.693</pub-id><pub-id pub-id-type="pmid">26069718</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stegenga</surname><given-names>ME</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Vail</surname><given-names>GM</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Haney</surname><given-names>DJ</given-names></name><name><surname>Williams</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis</article-title><source>Crit Care Med</source><year>2010</year><volume>38</volume><issue>2</issue><fpage>539</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181c02726</pub-id><pub-id pub-id-type="pmid">19851093</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>BB</given-names></name><name><surname>Keniston</surname><given-names>A</given-names></name><name><surname>Gajic</surname><given-names>O</given-names></name><name><surname>Trillo Alvarez</surname><given-names>CA</given-names></name><name><surname>Medvedev</surname><given-names>S</given-names></name><name><surname>Douglas</surname><given-names>IS</given-names></name></person-group><article-title>Diabetes mellitus does not adversely affect outcomes from a critical illness</article-title><source>Crit Care Med</source><year>2010</year><volume>38</volume><issue>1</issue><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181b9eaa5</pub-id><pub-id pub-id-type="pmid">19789450</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egi</surname><given-names>M</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Stachowski</surname><given-names>E</given-names></name><name><surname>French</surname><given-names>CJ</given-names></name><name><surname>Hart</surname><given-names>GK</given-names></name><name><surname>Hegarty</surname><given-names>C</given-names></name><etal/></person-group><article-title>Blood glucose concentration and outcome of critical illness: the impact of diabetes</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><issue>8</issue><fpage>2249</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318181039a</pub-id><pub-id pub-id-type="pmid">18664780</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Preiser</surname><given-names>JC</given-names></name><name><surname>Sprung</surname><given-names>CL</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Sakr</surname><given-names>Y</given-names></name></person-group><article-title>Insulin-treated diabetes is not associated with increased mortality in critically ill patients</article-title><source>Crit Care</source><year>2010</year><volume>14</volume><issue>1</issue><fpage>R12</fpage><pub-id pub-id-type="doi">10.1186/cc8866</pub-id><pub-id pub-id-type="pmid">20132545</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Hoyer</surname><given-names>D</given-names></name><name><surname>Hennen</surname><given-names>R</given-names></name><name><surname>Heinroth</surname><given-names>K</given-names></name><name><surname>Rauchhaus</surname><given-names>M</given-names></name><name><surname>Prondzinsky</surname><given-names>R</given-names></name><etal/></person-group><article-title>Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><issue>3</issue><fpage>967</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1097/CCM.0B013E3181653263</pub-id><pub-id pub-id-type="pmid">18431287</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kress</surname><given-names>JP</given-names></name><name><surname>Hall</surname><given-names>JB</given-names></name></person-group><article-title>ICU-acquired weakness and recovery from critical illness</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>17</issue><fpage>1626</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1209390</pub-id><pub-id pub-id-type="pmid">24758618</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchino</surname><given-names>S</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Doig</surname><given-names>GS</given-names></name><name><surname>Morimatsu</surname><given-names>H</given-names></name><name><surname>Morgera</surname><given-names>S</given-names></name><etal/></person-group><article-title>Acute renal failure in critically ill patients: a multinational, multicenter study</article-title><source>JAMA</source><year>2005</year><volume>294</volume><issue>7</issue><fpage>813</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/jama.294.7.813</pub-id><pub-id pub-id-type="pmid">16106006</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Paul</surname><given-names>SK</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Neil</surname><given-names>HA</given-names></name></person-group><article-title>10-year follow-up of intensive glucose control in type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>15</issue><fpage>1577</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0806470</pub-id><pub-id pub-id-type="pmid">18784090</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zink</surname><given-names>W</given-names></name><name><surname>Kollmar</surname><given-names>R</given-names></name><name><surname>Schwab</surname><given-names>S</given-names></name></person-group><article-title>Critical illness polyneuropathy and myopathy in the intensive care unit</article-title><source>Nat Rev Neurol</source><year>2009</year><volume>5</volume><issue>7</issue><fpage>372</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2009.75</pub-id><pub-id pub-id-type="pmid">19578344</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Berghe</surname><given-names>G</given-names></name><name><surname>Wilmer</surname><given-names>A</given-names></name><name><surname>Hermans</surname><given-names>G</given-names></name><name><surname>Meersseman</surname><given-names>W</given-names></name><name><surname>Wouters</surname><given-names>PJ</given-names></name><name><surname>Milants</surname><given-names>I</given-names></name><etal/></person-group><article-title>Intensive insulin therapy in the medical ICU</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><issue>5</issue><fpage>449</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa052521</pub-id><pub-id pub-id-type="pmid">16452557</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname><given-names>IM</given-names></name><name><surname>Adler</surname><given-names>AI</given-names></name><name><surname>Neil</surname><given-names>HA</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Manley</surname><given-names>SE</given-names></name><name><surname>Cull</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study</article-title><source>BMJ</source><year>2000</year><volume>321</volume><issue>7258</issue><fpage>405</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1136/bmj.321.7258.405</pub-id><pub-id pub-id-type="pmid">10938048</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Group</surname><given-names>AC</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Billot</surname><given-names>L</given-names></name><etal/></person-group><article-title>Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>24</issue><fpage>2560</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802987</pub-id><pub-id pub-id-type="pmid">18539916</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>S</given-names></name><name><surname>Wollersheim</surname><given-names>T</given-names></name><name><surname>Bierbrauer</surname><given-names>J</given-names></name><name><surname>Haas</surname><given-names>K</given-names></name><name><surname>Morgeli</surname><given-names>R</given-names></name><name><surname>Deja</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term recovery in critical illness myopathy is complete, contrary to polyneuropathy</article-title><source>Muscle Nerve</source><year>2014</year><volume>50</volume><issue>3</issue><fpage>431</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/mus.24175</pub-id><pub-id pub-id-type="pmid">24415656</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Miller</surname><given-names>ME</given-names></name><name><surname>Byington</surname><given-names>RP</given-names></name><name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></name><name><surname>Bigger</surname><given-names>JT</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Effects of intensive glucose lowering in type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>24</issue><fpage>2545</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802743</pub-id><pub-id pub-id-type="pmid">18539917</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuehl</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>MJ</given-names></name></person-group><article-title>Cardiovascular autonomic neuropathies as complications of diabetes mellitus</article-title><source>Nat Rev Endocrinol</source><year>2012</year><volume>8</volume><issue>7</issue><fpage>405</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2012.21</pub-id><pub-id pub-id-type="pmid">22371159</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pop-Busui</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>GW</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Fonseca</surname><given-names>V</given-names></name><name><surname>Fleg</surname><given-names>JL</given-names></name><name><surname>Hoogwerf</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><issue>7</issue><fpage>1578</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.2337/dc10-0125</pub-id><pub-id pub-id-type="pmid">20215456</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kar</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>KL</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Deane</surname><given-names>AM</given-names></name></person-group><article-title>Measurement of gastric emptying in the critically ill</article-title><source>Clin Nutr</source><year>2015</year><volume>34</volume><issue>4</issue><fpage>557</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2014.11.003</pub-id><pub-id pub-id-type="pmid">25491245</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>J</given-names></name><name><surname>Gager</surname><given-names>M</given-names></name><name><surname>Alder</surname><given-names>N</given-names></name><name><surname>Fawcett</surname><given-names>D</given-names></name><name><surname>Waldmann</surname><given-names>C</given-names></name><name><surname>Quinlan</surname><given-names>J</given-names></name></person-group><article-title>A self-report-based study of the incidence and associations of sexual dysfunction in survivors of intensive care treatment</article-title><source>Intensive Care Med</source><year>2006</year><volume>32</volume><issue>3</issue><fpage>445</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/s00134-005-0048-7</pub-id><pub-id pub-id-type="pmid">16482394</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reitz</surname><given-names>A</given-names></name></person-group><article-title>Lower urinary tract dysfunction in critical illness polyneuropathy</article-title><source>NeuroRehabilitation</source><year>2013</year><volume>33</volume><issue>2</issue><fpage>329</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">23949055</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinik</surname><given-names>AI</given-names></name><name><surname>Maser</surname><given-names>RE</given-names></name><name><surname>Mitchell</surname><given-names>BD</given-names></name><name><surname>Freeman</surname><given-names>R</given-names></name></person-group><article-title>Diabetic autonomic neuropathy</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><issue>5</issue><fpage>1553</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.5.1553</pub-id><pub-id pub-id-type="pmid">12716821</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>M</given-names></name><name><surname>Cass</surname><given-names>A</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Gattas</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><etal/></person-group><article-title>Long-term survival and dialysis dependency following acute kidney injury in intensive care: extended follow-up of a randomized controlled trial</article-title><source>PLoS Med</source><year>2014</year><volume>11</volume><issue>2</issue><fpage>e1001601</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1001601</pub-id><pub-id pub-id-type="pmid">24523666</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korkeila</surname><given-names>M</given-names></name><name><surname>Ruokonen</surname><given-names>E</given-names></name><name><surname>Takala</surname><given-names>J</given-names></name></person-group><article-title>Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care</article-title><source>Intensive Care Med</source><year>2000</year><volume>26</volume><issue>12</issue><fpage>1824</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1007/s001340000726</pub-id><pub-id pub-id-type="pmid">11271091</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlstrom</surname><given-names>A</given-names></name><name><surname>Tallgren</surname><given-names>M</given-names></name><name><surname>Peltonen</surname><given-names>S</given-names></name><name><surname>Rasanen</surname><given-names>P</given-names></name><name><surname>Pettila</surname><given-names>V</given-names></name></person-group><article-title>Survival and quality of life of patients requiring acute renal replacement therapy</article-title><source>Intensive Care Med</source><year>2005</year><volume>31</volume><issue>9</issue><fpage>1222</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s00134-005-2681-6</pub-id><pub-id pub-id-type="pmid">16049711</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astor</surname><given-names>BC</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>Gansevoort</surname><given-names>RT</given-names></name><name><surname>van der Velde</surname><given-names>M</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts</article-title><source>Kidney Int</source><year>2011</year><volume>79</volume><issue>12</issue><fpage>1331</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/ki.2010.550</pub-id><pub-id pub-id-type="pmid">21289598</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klausen</surname><given-names>K</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Feldt-Rasmussen</surname><given-names>B</given-names></name><name><surname>Jensen</surname><given-names>G</given-names></name><name><surname>Clausen</surname><given-names>P</given-names></name><name><surname>Scharling</surname><given-names>H</given-names></name><etal/></person-group><article-title>Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>1</issue><fpage>32</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000133312.96477.48</pub-id><pub-id pub-id-type="pmid">15210602</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carnethon</surname><given-names>MR</given-names></name><name><surname>Prineas</surname><given-names>RJ</given-names></name><name><surname>Temprosa</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>ZM</given-names></name><name><surname>Uwaifo</surname><given-names>G</given-names></name><name><surname>Molitch</surname><given-names>ME</given-names></name></person-group><article-title>The association among autonomic nervous system function, incident diabetes, and intervention arm in the diabetes prevention program</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><issue>4</issue><fpage>914</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2337/diacare.29.04.06.dc05-1729</pub-id><pub-id pub-id-type="pmid">16567837</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaede</surname><given-names>P</given-names></name><name><surname>Vedel</surname><given-names>P</given-names></name><name><surname>Parving</surname><given-names>HH</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name></person-group><article-title>Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study</article-title><source>Lancet</source><year>1999</year><volume>353</volume><issue>9153</issue><fpage>617</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)07368-1</pub-id><pub-id pub-id-type="pmid">10030326</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Cleary</surname><given-names>PA</given-names></name><name><surname>Backlund</surname><given-names>JY</given-names></name><name><surname>Genuth</surname><given-names>SM</given-names></name><name><surname>Lachin</surname><given-names>JM</given-names></name><name><surname>Orchard</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><issue>25</issue><fpage>2643</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa052187</pub-id><pub-id pub-id-type="pmid">16371630</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duckworth</surname><given-names>W</given-names></name><name><surname>Abraira</surname><given-names>C</given-names></name><name><surname>Moritz</surname><given-names>T</given-names></name><name><surname>Reda</surname><given-names>D</given-names></name><name><surname>Emanuele</surname><given-names>N</given-names></name><name><surname>Reaven</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Glucose control and vascular complications in veterans with type 2 diabetes</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><issue>2</issue><fpage>129</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0808431</pub-id><pub-id pub-id-type="pmid">19092145</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwashyna</surname><given-names>TJ</given-names></name><name><surname>Netzer</surname><given-names>G</given-names></name></person-group><article-title>The burdens of survivorship: an approach to thinking about long-term outcomes after critical illness</article-title><source>Semin Respir Crit Care Med</source><year>2012</year><volume>33</volume><issue>4</issue><fpage>327</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1321982</pub-id><pub-id pub-id-type="pmid">22875378</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modrykamien</surname><given-names>AM</given-names></name></person-group><article-title>The ICU, follow-up clinic: a new paradigm for intensivists</article-title><source>Respir Care</source><year>2012</year><volume>57</volume><issue>5</issue><fpage>764</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">22152275</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>JF</given-names></name><name><surname>Thomsen</surname><given-names>T</given-names></name><name><surname>Overgaard</surname><given-names>D</given-names></name><name><surname>Bestle</surname><given-names>MH</given-names></name><name><surname>Christensen</surname><given-names>D</given-names></name><name><surname>Egerod</surname><given-names>I</given-names></name></person-group><article-title>Impact of follow-up consultations for ICU survivors on post-ICU syndrome: a systematic review and meta-analysis</article-title><source>Intensive Care Med</source><year>2015</year><volume>41</volume><issue>5</issue><fpage>763</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/s00134-015-3689-1</pub-id><pub-id pub-id-type="pmid">25731633</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuthbertson</surname><given-names>BH</given-names></name><name><surname>Rattray</surname><given-names>J</given-names></name><name><surname>Campbell</surname><given-names>MK</given-names></name><name><surname>Gager</surname><given-names>M</given-names></name><name><surname>Roughton</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><etal/></person-group><article-title>The PRaCTICaL study of nurse led, intensive care follow-up programmes for improving long term outcomes from critical illness: a pragmatic randomised controlled trial</article-title><source>BMJ</source><year>2009</year><volume>339</volume><fpage>b3723</fpage><pub-id pub-id-type="doi">10.1136/bmj.b3723</pub-id><pub-id pub-id-type="pmid">19837741</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>TS</given-names></name><name><surname>Salisbury</surname><given-names>LG</given-names></name><name><surname>Merriweather</surname><given-names>JL</given-names></name><name><surname>Boyd</surname><given-names>JA</given-names></name><name><surname>Griffith</surname><given-names>DM</given-names></name><name><surname>Huby</surname><given-names>G</given-names></name><etal/></person-group><article-title>Increased hospital-based physical rehabilitation and information provision after intensive care unit discharge: the RECOVER randomized clinical trial</article-title><source>JAMA Intern Med</source><year>2015</year><volume>175</volume><issue>6</issue><fpage>901</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2015.0822</pub-id><pub-id pub-id-type="pmid">25867659</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">National Institute for Health and Clinical Excellence. Rehabilitation after critical illness. London: National Institute for Health and Clinical Excellence. 2009. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/cg83">www.nice.org.uk/cg83</ext-link>. Accessed 26 Nov 2015.</mixed-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Tetzlaff</surname><given-names>JM</given-names></name><name><surname>Gotzsche</surname><given-names>PC</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Mann</surname><given-names>H</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><etal/></person-group><article-title>SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials</article-title><source>BMJ</source><year>2013</year><volume>346</volume><fpage>e7586</fpage><pub-id pub-id-type="doi">10.1136/bmj.e7586</pub-id><pub-id pub-id-type="pmid">23303884</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>D</given-names></name></person-group><article-title>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</article-title><source>JAMA</source><year>2001</year><volume>285</volume><issue>15</issue><fpage>1987</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1001/jama.285.15.1987</pub-id><pub-id pub-id-type="pmid">11308435</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colman</surname><given-names>PG</given-names></name><name><surname>Thomas</surname><given-names>DW</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name><name><surname>Welborn</surname><given-names>TA</given-names></name><name><surname>Garcia-Webb</surname><given-names>P</given-names></name><name><surname>Moore</surname><given-names>MP</given-names></name></person-group><article-title>New classification and criteria for diagnosis of diabetes mellitus. Position Statement from the Australian Diabetes Society, New Zealand Society for the Study of Diabetes, Royal College of Pathologists of Australasia and Australasian Association of Clinical Biochemists</article-title><source>Med J Aust</source><year>1999</year><volume>170</volume><issue>8</issue><fpage>375</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10327951</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>d'Emden</surname><given-names>MC</given-names></name><name><surname>Shaw</surname><given-names>JE</given-names></name><name><surname>Colman</surname><given-names>PG</given-names></name><name><surname>Colagiuri</surname><given-names>S</given-names></name><name><surname>Twigg</surname><given-names>SM</given-names></name><name><surname>Jones</surname><given-names>GR</given-names></name><etal/></person-group><article-title>The role of HbA1c in the diagnosis of diabetes mellitus in Australia</article-title><source>Med J Aust</source><year>2012</year><volume>197</volume><issue>4</issue><fpage>220</fpage><lpage>1</lpage><pub-id pub-id-type="doi">10.5694/mja12.10988</pub-id><pub-id pub-id-type="pmid">22900870</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Takala</surname><given-names>J</given-names></name><name><surname>Willatts</surname><given-names>S</given-names></name><name><surname>De Mendonca</surname><given-names>A</given-names></name><name><surname>Bruining</surname><given-names>H</given-names></name><etal/></person-group><article-title>The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on sepsis-related problems of the European Society of Intensive Care Medicine</article-title><source>Intensive Care Med</source><year>1996</year><volume>22</volume><issue>7</issue><fpage>707</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/BF01709751</pub-id><pub-id pub-id-type="pmid">8844239</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Draper</surname><given-names>EA</given-names></name><name><surname>Wagner</surname><given-names>DP</given-names></name><name><surname>Zimmerman</surname><given-names>JE</given-names></name></person-group><article-title>APACHE II: a severity of disease classification system</article-title><source>Crit Care Med</source><year>1985</year><volume>13</volume><issue>10</issue><fpage>818</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1097/00003246-198510000-00009</pub-id><pub-id pub-id-type="pmid">3928249</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Mehta</surname><given-names>RL</given-names></name><name><surname>Palevsky</surname><given-names>P</given-names></name></person-group><article-title>Acute renal failure&#x02014;definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group</article-title><source>Crit Care</source><year>2004</year><volume>8</volume><issue>4</issue><fpage>R204</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/cc2872</pub-id><pub-id pub-id-type="pmid">15312219</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockwood</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>MacKnight</surname><given-names>C</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Hogan</surname><given-names>DB</given-names></name><name><surname>McDowell</surname><given-names>I</given-names></name><etal/></person-group><article-title>A global clinical measure of fitness and frailty in elderly people</article-title><source>CMAJ</source><year>2005</year><volume>173</volume><issue>5</issue><fpage>489</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1503/cmaj.050051</pub-id><pub-id pub-id-type="pmid">16129869</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RM</given-names></name><name><surname>Holmes</surname><given-names>YR</given-names></name><name><surname>Chenier</surname><given-names>TC</given-names></name><name><surname>Joiner</surname><given-names>CH</given-names></name></person-group><article-title>Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><issue>1</issue><fpage>163</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.1.163</pub-id><pub-id pub-id-type="pmid">12502674</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>NW</given-names></name><name><surname>Conn</surname><given-names>JJ</given-names></name><name><surname>d'Emden</surname><given-names>MC</given-names></name><name><surname>Gunton</surname><given-names>JE</given-names></name><name><surname>Jenkins</surname><given-names>AJ</given-names></name><name><surname>Ross</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus</article-title><source>Med J Aust</source><year>2009</year><volume>191</volume><issue>6</issue><fpage>339</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">19769558</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Endocrinology Expert Group. Diabetes. In: eTG complete. Melbourne: Therapeutic Guidelines Limited. Revised 2013 Oct. <ext-link ext-link-type="uri" xlink:href="http://online.tg.org.au/complete">http://online.tg.org.au/complete</ext-link>. Accessed 30 Nov 2015.</mixed-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadban</surname><given-names>S</given-names></name><name><surname>Howell</surname><given-names>M</given-names></name><name><surname>Twigg</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Jerums</surname><given-names>G</given-names></name><name><surname>Cass</surname><given-names>A</given-names></name><etal/></person-group><article-title>The CARI guidelines. Assessment of kidney function in type 2 diabetes</article-title><source>Nephrology (Carlton)</source><year>2010</year><volume>15</volume><issue>Suppl 1</issue><fpage>S146</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1797.2010.01239.x</pub-id><pub-id pub-id-type="pmid">20591027</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>WH</given-names></name><name><surname>Pop-Busui</surname><given-names>R</given-names></name><name><surname>Braffett</surname><given-names>BH</given-names></name><name><surname>Martin</surname><given-names>CL</given-names></name><name><surname>Cleary</surname><given-names>PA</given-names></name><name><surname>Albers</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications</article-title><source>Diabet Med</source><year>2012</year><volume>29</volume><issue>7</issue><fpage>937</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2012.03644.x</pub-id><pub-id pub-id-type="pmid">22417277</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spallone</surname><given-names>V</given-names></name><name><surname>Ziegler</surname><given-names>D</given-names></name><name><surname>Freeman</surname><given-names>R</given-names></name><name><surname>Bernardi</surname><given-names>L</given-names></name><name><surname>Frontoni</surname><given-names>S</given-names></name><name><surname>Pop-Busui</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management</article-title><source>Diabetes Metab Res Rev</source><year>2011</year><volume>27</volume><issue>7</issue><fpage>639</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/dmrr.1239</pub-id><pub-id pub-id-type="pmid">21695768</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardi</surname><given-names>L</given-names></name><name><surname>Spallone</surname><given-names>V</given-names></name><name><surname>Stevens</surname><given-names>M</given-names></name><name><surname>Hilsted</surname><given-names>J</given-names></name><name><surname>Frontoni</surname><given-names>S</given-names></name><name><surname>Pop-Busui</surname><given-names>R</given-names></name><etal/></person-group><article-title>Methods of investigation for cardiac autonomic dysfunction in human research studies</article-title><source>Diabetes Metab Res Rev</source><year>2011</year><volume>27</volume><issue>7</issue><fpage>654</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1002/dmrr.1224</pub-id><pub-id pub-id-type="pmid">21695761</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lennon</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>L</given-names></name></person-group><article-title>The modified rivermead mobility index: validity and reliability</article-title><source>Disabil Rehabil</source><year>2000</year><volume>22</volume><issue>18</issue><fpage>833</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1080/09638280050207884</pub-id><pub-id pub-id-type="pmid">11197520</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>AS</given-names></name><name><surname>Snaith</surname><given-names>RP</given-names></name></person-group><article-title>The hospital anxiety and depression scale</article-title><source>Acta Psychiatr Scand</source><year>1983</year><volume>67</volume><issue>6</issue><fpage>361</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1983.tb09716.x</pub-id><pub-id pub-id-type="pmid">6880820</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunstan</surname><given-names>DW</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name><name><surname>Welborn</surname><given-names>TA</given-names></name><name><surname>De Courten</surname><given-names>MP</given-names></name><name><surname>Cameron</surname><given-names>AJ</given-names></name><name><surname>Sicree</surname><given-names>RA</given-names></name><etal/></person-group><article-title>The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><issue>5</issue><fpage>829</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.2337/diacare.25.5.829</pub-id><pub-id pub-id-type="pmid">11978676</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>WL</given-names></name><name><surname>Cox</surname><given-names>DJ</given-names></name><name><surname>Gonder-Frederick</surname><given-names>LA</given-names></name><name><surname>Julian</surname><given-names>D</given-names></name><name><surname>Schlundt</surname><given-names>D</given-names></name><name><surname>Polonsky</surname><given-names>W</given-names></name></person-group><article-title>Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms</article-title><source>Diabetes Care</source><year>1995</year><volume>18</volume><issue>4</issue><fpage>517</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.2337/diacare.18.4.517</pub-id><pub-id pub-id-type="pmid">7497862</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herdman</surname><given-names>M</given-names></name><name><surname>Gudex</surname><given-names>C</given-names></name><name><surname>Lloyd</surname><given-names>A</given-names></name><name><surname>Janssen</surname><given-names>M</given-names></name><name><surname>Kind</surname><given-names>P</given-names></name><name><surname>Parkin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)</article-title><source>Qual Life Res</source><year>2011</year><volume>20</volume><issue>10</issue><fpage>1727</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s11136-011-9903-x</pub-id><pub-id pub-id-type="pmid">21479777</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Sherbourne</surname><given-names>CD</given-names></name></person-group><article-title>The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection</article-title><source>Med Care</source><year>1992</year><volume>30</volume><issue>6</issue><fpage>473</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1097/00005650-199206000-00002</pub-id><pub-id pub-id-type="pmid">1593914</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heyland</surname><given-names>DK</given-names></name><name><surname>Hopman</surname><given-names>W</given-names></name><name><surname>Coo</surname><given-names>H</given-names></name><name><surname>Tranmer</surname><given-names>J</given-names></name><name><surname>McColl</surname><given-names>MA</given-names></name></person-group><article-title>Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><issue>11</issue><fpage>3599</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1097/00003246-200011000-00006</pub-id><pub-id pub-id-type="pmid">11098960</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paratz</surname><given-names>JD</given-names></name><name><surname>Kenardy</surname><given-names>J</given-names></name><name><surname>Mitchell</surname><given-names>G</given-names></name><name><surname>Comans</surname><given-names>T</given-names></name><name><surname>Coyer</surname><given-names>F</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><etal/></person-group><article-title>IMPOSE (IMProving Outcomes after Sepsis)&#x02014;the effect of a multidisciplinary follow-up service on health-related quality of life in patients postsepsis syndromes&#x02014;a double-blinded randomised controlled trial: protocol</article-title><source>BMJ Open</source><year>2014</year><volume>4</volume><issue>5</issue><fpage>e004966</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2014-004966</pub-id><pub-id pub-id-type="pmid">24861549</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>C</given-names></name><name><surname>Karalapillai</surname><given-names>DK</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name><name><surname>Glassford</surname><given-names>NG</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name></person-group><article-title>Predicting intensive care and hospital outcome with the Dalhousie Clinical Frailty Scale: a pilot assessment</article-title><source>Anaesth Intensive Care</source><year>2015</year><volume>43</volume><issue>3</issue><fpage>361</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25943611</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagshaw</surname><given-names>SM</given-names></name><name><surname>Stelfox</surname><given-names>HT</given-names></name><name><surname>McDermid</surname><given-names>RC</given-names></name><name><surname>Rolfson</surname><given-names>DB</given-names></name><name><surname>Tsuyuki</surname><given-names>RT</given-names></name><name><surname>Baig</surname><given-names>N</given-names></name><etal/></person-group><article-title>Association between frailty and short- and long-term outcomes among critically ill patients: a multicentre prospective cohort study</article-title><source>CMAJ</source><year>2014</year><volume>186</volume><issue>2</issue><fpage>E95</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1503/cmaj.130639</pub-id><pub-id pub-id-type="pmid">24277703</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unroe</surname><given-names>M</given-names></name><name><surname>Kahn</surname><given-names>JM</given-names></name><name><surname>Carson</surname><given-names>SS</given-names></name><name><surname>Govert</surname><given-names>JA</given-names></name><name><surname>Martinu</surname><given-names>T</given-names></name><name><surname>Sathy</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: a cohort study</article-title><source>Ann Intern Med</source><year>2010</year><volume>153</volume><issue>3</issue><fpage>167</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-153-3-201008030-00007</pub-id><pub-id pub-id-type="pmid">20679561</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>DB</given-names></name><name><surname>Chapple</surname><given-names>LS</given-names></name><name><surname>O'Connor</surname><given-names>SN</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Buhr</surname><given-names>H</given-names></name><name><surname>Chapman</surname><given-names>M</given-names></name><etal/></person-group><article-title>The effect of augmenting early nutritional energy delivery on quality of life and employment status one year after ICU admission</article-title><source>Anaesth Intensive Care</source><year>2016</year><volume>44</volume><issue>3</issue><fpage>406</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">27246942</pub-id></element-citation></ref></ref-list></back></article>